ArticleCell death & disease2025

High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers.

Peng Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.